BeiGene’s Tislelizumab Receives NMPA’s Approval for the Treatment of Recurrent or Metastatic Nasopharyngeal Cancer
June 10, 2022
BeiGene Reports Results of Tislelizumab in P-III (RATIONALE 306) Trial as 1L Treatment of Advanced Esophageal Squamous Cell Carcin...
April 27, 2022
BeiGene Provides Updates of Tislelizumab in P-III (RATIONALE-309) Trial as 1L Treatment of Recurrent or Metastatic Nasopharyngeal...
April 19, 2022
BeiGene’s Tislelizumab Receives the NMPA’s Approval as a 2L Treatment for Esophageal Squamous Cell Carcinoma
April 18, 2022
BeiGene’s Tislelizumab Receives the NMPA Approval for Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors
March 14, 2022
BeiGene’s Tislelizumab Receives NMPA’s Approval as 2L & 3L Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
January 6, 2022
No more records!
Incisive News in 3 Shots.
First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
Terms of Service
Copyright © 2022 PharmaShots - All Rights Reserved.